Generic Drug

February 27, 2012

A drug product sold under the provisions of Section 505(j) of the Federal Food, Drug and Cosmetic Act. The Abbreviated New Drug Application (ANDA) was enabled through the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman). The ANDA must contain (1) information to show conditions of the proposed generic drug's labeling have been previously approved for the "reference listed drug" (RLD), (2) that the generic drug is pharmaceutically equivalent to the RLD (same active ingredient, route of administration, dosage form and strength), (3) that the generic drug is bioequivalent to the RLD, (4) the generic drug must have the same labeling as the RLD, and (5) the generic drug must be manufactured in compliance with cGMPs. Finally, with regard to patents, the sponsor of a generic drug application must certify to the FDA that (I) information on any patents were not filed by the NDA holder with FDA, (II) relevant patent(s) have expired, (III) relevant patent(s) will expire on some future date, or (IV) relevant patent(s) are invalid or would not be infringed by the manufacture of a generic version.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision